This trend can been also seen in the recent approved personalized therapies, such as osimertinib to be used in Epidermal Growth Factor Receptor (EGFR) exon 20 mutated lung carcinomas after failure of first line Tyrosine kinase inhibitors (TKI), or crizotinib (Xalkori, Pfizer) for first line metastatic ROS1 positive lung carcinomas, or even alectinib for anaplastic lymphoma kinase (ALK) positive carcinomas progressing after crizotinib approved for ROS1-positive metastatic non-small cell lung cancer (NSCLC). This evidence concerns the gene EGFR and carcinoma.